Pharmaceutical & Biotechnology

In pharma, the systems an AI agent reaches into are the regulated crown jewels: LIMS, ELN, EDC, eTMF, CTMS, MES, pharmacovigilance and safety databases, and the data lakes behind them. MCP is the connection layer, and the moment an agent calls into one of those systems, every data-integrity, access-control, and audit obligation is triggered at once. Against the 2026–2030 patent “super-cliff,” the pressure to discover and approve faster with AI is intense — so the question is how to use it without creating a compliance, IP, or patient-safety incident.

​

The opportunity and the bind

The thing blocking safe scaling is a governance gap. Recent industry analysis found that the large majority of organizations operate without basic technical safeguards over what flows into AI tools, even as AI security incidents climb. “Shadow AI” is an acute concern here precisely because of what employees can leak — drug IP, clinical-trial data, and patient health information that can end up training a public model and cannot be retrieved or deleted afterward. The collision is concrete: HIPAA expects an audit trail for every access to patient data; 21 CFR Part 11 expects validated systems and reviewable records; GDPR requires the ability to delete personal data on request. Public AI platforms meet none of those, and the organization owns the gap. The industry is calling for the answer in exactly our category language — continuous monitoring of AI interactions through an AI data gateway. The gateway is the single point where trade-secret and patient data can be detected and stopped before it reaches a model, and where every call into a regulated system is attributed to a specific identity and recorded.

​

The regulatory reality

In January 2026 the FDA and EMA jointly released the Guiding Principles of Good AI Practice in Drug Development — ten principles spanning the lifecycle, emphasizing risk-based validation, transparency, and robust data governance, and extending existing GxP software-validation thinking to AI. The message inspectors will apply: AI governance must be explainable, traceable, and inspection-ready, no different from any other GxP system. That is the most authoritative anchor for an AI-control conversation in pharma, and it points squarely at the controls a gateway provides.

• 21 CFR Part 11 and EU Annex 11 — systems handling regulated data need reviewable, attributable audit trails and secure access controls. MCP Manager produces a per-identity, searchable record of every agent call and enforces scoped access in front of those systems.
• ALCOA+ “attributable” — every record must tie to the identity that created it, the data-integrity gap most often faulted on a Form FDA 483. MCP Manager brokers identity so every call carries the real user or agent behind it.
• GDPR special-category data and the right to erasure — patient and trial data must be minimized and controllable, which a public model that has absorbed it cannot satisfy. MCP Manager detects and redacts that data before it reaches the model.
• The EU AI Act — most clinical-facing AI carries traceability, logging, and human-oversight duties from 2 August 2026. MCP Manager logs every interaction and lets you scope and gate which agents reach which systems.

The IP row is the one that resonates first with this audience: the gateway can detect proprietary molecular, clinical, or trade-secret data and stop it from reaching a public model in the first place, rather than discovering the leak in an incident review.

​

How MCP Manager governs pharma AI

• Sensitive-data enforcement in flight. Gateway rules inspect every message in both directions. Microsoft Presidio supplies trained classifiers, regex catches structured identifiers, and custom rule engines connect an internal DLP system. Five actions — block, redact, replace, mask, hash — apply inline, each set to fail closed if you choose.
• Per-identity attribution. Every call records the requesting identity, the tool, the payloads, the latency, and the enforcement verdict, supporting the “attributable” pillar of ALCOA+ and a record you can search and export. See Audit & observability.
• Governed access to regulated systems. Capability-based RBAC, per-team and per-identity tool scoping, SSO, and SCIM 2.0 decide which agents reach LIMS, EDC, or a safety database, and which tools they may call.
• Tool integrity against rug pulls. Tool-change protection pins a tool by name, title, or description so a server cannot quietly change its behavior after qualification.
• Identity and encryption. Enforced OAuth with PKCE, identity brokering so credentials never live in the client, AES-256-GCM credential encryption under rotating keys, and TLS on every hop. See Architecture & Trust.
• Keep source data in your environment. Servers behind workstation and managed deployments stay in your infrastructure, gateway rules redact before logging, and a self-hosted collector keeps your audit copy in your own region.

​

Why Usercentrics

A pharma buyer’s decision is dominated by Quality, Regulatory, Privacy, and Security, and the unspoken question is “why trust a young product with our most regulated data flows?” The answer is the parent company. MCP Manager is built by Usercentrics, Europe’s largest consent management platform, whose entire heritage is enforceable consent and compliance at scale under GDPR — billions of consent signals every month across 100+ countries. Most MCP-gateway alternatives come from infrastructure or developer-tooling backgrounds; none carries a compliance and consent pedigree. Usercentrics already helps organizations prove that data is used only under a valid legal basis; MCP Manager applies that same discipline to the AI layer, so a pharma company can put AI to work on its most valuable data without losing the ability to defend it to an inspector. The platform runs inside Usercentrics’ own audited cloud and security program — review its posture at the Usercentrics trust center.

​

Further reading

​

External sources